Eisai Co., Ltd.
Clinical trials sponsored by Eisai Co., Ltd., explained in plain language.
A Japanese pharmaceutical company known for neurology and oncology drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New drug combo targets tough breast cancer in early trial
Disease control CompletedThis early-phase study tests a new drug called E7090, alone or with other cancer medicines, in people with a common type of advanced breast cancer (ER+, HER2-). The main goal is to find safe doses and understand side effects. About 51 participants will take part to guide future r…
Phase: PHASE1 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Targeted drug shows promise for rare bile duct cancer
Disease control CompletedThis study tested an experimental drug called E7090 in 63 people with advanced bile duct cancer that has a specific genetic change (FGFR2 fusion). Participants had already tried chemotherapy without success. The goal was to see if the drug could shrink tumors. Results help determ…
Phase: PHASE2 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug E7090 tested in patients with advanced solid tumors
Disease control CompletedThis early-phase study tested an experimental drug called E7090 in 40 adults with advanced solid tumors that had not responded to standard treatments. The goal was to find the safest dose and check for early signs of effectiveness, especially in patients whose tumors have certain…
Phase: PHASE1 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New hope for breast cancer: early trial of H3B-6545 in japanese women
Disease control CompletedThis early-phase study tested a new oral drug called H3B-6545 in 33 Japanese women with a common type of breast cancer (ER-positive, HER2-negative). The main goal was to see if the drug is safe and tolerable, and to find the right dose for Japanese patients. Participants had alre…
Phase: PHASE1 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC